FGEN
FibrogenยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
FGEN Profile
Fibrogen, Inc.
A biopharmaceutical company that developing novel therapeutic agents to treat anemia, fibrotic disease, and cancer
350 Bay Street, Suite 100 #6009, San Francisco, CA 94133
--
Fibrogen, Inc., was incorporated in Delaware in 1993. The company is a biopharmaceutical company focused on the development of new therapies in the frontiers of cancer biology and anemia. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46 for the treatment of metastatic castration-resistant prostate cancer and potentially other cancers. The program also includes the development of FG-3180, a related CD46 targeted positron emission tomography biomarker and imaging agent.
